Avanos (NYSE: AVNS) grants options and TRSUs to SVP Delgado

Rhea-AI Filing Summary

Avanos Medical SVP of Operations Sigfrido Delgado received new equity awards. He was granted 37,782 employee stock options to buy Common Stock at $13.69 per share, expiring on March 13, 2036. He was also granted 15,886 time-based restricted share units that vest in stages between March 2027 and March 2029.

Following these awards, he directly holds 59,696 stock options and 60,005 shares of Common Stock. The TRSUs are the economic equivalent of common shares but will only convert into stock as they vest under Avanos Medical's 2021 Long Term Incentive Plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Delgado Sigfrido

Role SVP, Operations

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	37,782	$0.00	--
Grant/Award	Common Stock	15,886	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 59,696 shares (Direct); Common Stock — 60,005 shares (Direct)

Footnotes (1)

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Key Figures

Stock options granted: 37,782 options Option exercise price: $13.69 per share Options held after grant: 59,696 options +5 more

8 metrics

Stock options granted 37,782 options Employee Stock Option grant on March 13, 2026

Option exercise price $13.69 per share Strike price for 37,782 options expiring March 13, 2036

Options held after grant 59,696 options Total employee stock options directly held after transactions

Common shares granted 15,886 TRSUs Time-based restricted share units awarded March 13, 2026

Common shares held after grant 60,005 shares Direct Common Stock holdings after TRSU award

TRSU vesting schedule 1/3 each in 2027, 2028, 2029 Vests March 13, 2027, 2028, and 2029

Option vesting schedule 30%, 30%, 40% Vests March 13, 2027; March 13, 2028; March 13, 2029

Option expiration March 13, 2036 Expiration date for 37,782 granted options

Key Terms

Employee Stock Option (right to buy), time-based restricted share units (TRSUs), 2021 Long Term Incentive Plan, economic equivalent of one share of Common Stock

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

time-based restricted share units (TRSUs) financial

"Represents time-based restricted share units (TRSUs) awarded pursuant"

2021 Long Term Incentive Plan financial

"awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended"

economic equivalent of one share of Common Stock financial

"Each TRSU is the economic equivalent of one share of Common Stock"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Delgado Sigfrido

(Last) (First) (Middle)

5405 WINDWARD PKWY

(Street)

ALPHARETTA GEORGIA 30004-4667

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/17/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		15,886(1)	A	$0	60,005	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.69	03/13/2026		A		37,782		(2)	03/13/2036	Common Stock	37,782	$0	59,696	D

Explanation of Responses:

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.

2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Remarks:

This Form 4/A is being filed to correct an error in the calculation of the number of stock options issued to the Reporting Person on March 13, 2026 pursuant to the Issuer's 2021 Long-Term Incentive Plan, as amended.

	/s/ John Hurley, as attorney-in-fact for Sigfrido Delgado	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AVNS report for Sigfrido Delgado on this Form 4/A?

AVNS reported that SVP of Operations Sigfrido Delgado received equity awards, not open-market trades. He was granted stock options and time-based restricted share units as part of Avanos Medical’s 2021 Long Term Incentive Plan, increasing his direct equity-based compensation stake.

How many stock options did the AVNS SVP receive in this grant?

Sigfrido Delgado received 37,782 employee stock options in this award. Each option gives him the right to buy one share of Avanos Medical Common Stock at $13.69 per share, with an expiration date of March 13, 2036, if the options are vested and exercised.

What restricted share units did AVNS grant to Sigfrido Delgado?

Avanos Medical granted Delgado 15,886 time-based restricted share units. These TRSUs are tied to the company’s 2021 Long Term Incentive Plan and are the economic equivalent of one share of Common Stock each, subject to vesting milestones over three future dates.

What is the vesting schedule for Sigfrido Delgado’s AVNS TRSUs?

The 15,886 TRSUs will vest in three installments over time. One-third vests on March 13, 2027, one-third on March 13, 2028, and the final one-third on March 13, 2029, assuming continued eligibility under Avanos Medical’s long-term incentive plan.

What is the vesting schedule for the AVNS stock options granted to Delgado?

The stock options vest 30% on March 13, 2027, 30% on March 13, 2028, and the remaining 40% on March 13, 2029. Once vested, these options allow Sigfrido Delgado to purchase Avanos Medical Common Stock at the fixed $13.69 exercise price before expiration.

How many AVNS shares and options does Sigfrido Delgado hold after these grants?

After the reported transactions, Delgado directly holds 60,005 shares of Avanos Medical Common Stock. He also holds 59,696 employee stock options following the new grant, reflecting his ongoing equity-based compensation as SVP of Operations at the company.